On July 22, 2026, Brent Franson (@brentfranson) announced the launch of Death Clock, an iOS app that pairs a free basic blood test with an AI model that predicts an individual’s date of death and then generates a plan to extend it.
https://x.com/brentfranson/status/2079947976785739960 Franson’s 12‑part X thread outlined the product’s three‑tiered offering. The free tier includes a comprehensive metabolic panel, a complete blood count, and high‑sensitivity C‑reactive protein (hs‑CRP). Users can order any additional panel a la carte, and the service claims access to more than 4,500 Labcorp and Quest locations nationwide. A premium subscription, priced at $69 per year, adds ApoB, HbA1c, Vitamin D, and an expanded “full panel.” The app aggregates the lab results with wearables and medical history, feeding the data into an AI that produces a single “death date” and a gamified plan to “move” that date forward.
The AI’s methodology is described as built on “1,200+ clinical longevity studies” and overseen by a clinical board chaired by a Stanford professor of medicine. The thread includes a link to the app’s Apple Store page (Death Clock – The Life Lab) and a website at http://DeathClock.AI.
Business model and incentives
Franson positions the free basic test as a loss‑leader to acquire user data and funnel participants into the paid premium. The $69/year fee is modest compared to traditional concierge health services, yet the model hinges on scaling a high‑volume, low‑margin lab partnership while monetizing the AI‑generated longevity roadmap. The thread does not disclose any investors or prior funding rounds, leaving the runway and valuation opaque.
Regulatory and privacy considerations
Offering a nationwide blood draw through Labcorp and Quest implies compliance with CLIA certification, but the thread provides no detail on FDA clearance for the AI prediction algorithm. Predicting a specific death date raises potential liability and ethical concerns, especially if users rely on the forecast for financial or medical decisions. Franson explicitly states the company does not share or sell user data, responding to a query from @psyopwhite, though no independent audit or privacy policy link is provided.
Competitive landscape
Death Clock joins a crowded field of direct‑to‑consumer lab testing platforms such as Everlywell and LetsGetChecked, which typically offer panels for a flat fee without AI prognosis. The novelty here is the amalgamation of predictive modeling with a gamified engagement loop, reminiscent of health‑tracking apps that reward behavior change. However, the claim to add “years” to a user’s lifespan is unsubstantiated by peer‑reviewed evidence; the thread cites a Wall Street Journal quote—“Tech that will change your life”—without a link to the article, and no clinical trial data is presented.
Founder background
Public information on Franson’s prior ventures or professional history is limited. The X thread is his first public announcement of Death Clock, and RuntimeWire has not previously covered him or the company. What’s next
The launch hinges on user acquisition at scale, regulatory clarity for AI‑driven prognostics, and the ability to convert free users to paying subscribers. If the model delivers measurable health improvements, it could attract venture interest; if not, the promised “years added to your life” may remain marketing hype.
The announcement marks a bold entry into the consumer longevity space, marrying mass‑market lab testing with an AI‑generated life‑expectancy score. Whether the venture can navigate the medical‑regulatory minefield while sustaining a viable business remains an open question.